Previously, EU national regulators received dozens of cases of cerebrovascular thrombosis following OXFAM vaccination, with some people dying as a result, prompting several countries to suspend OXFAM vaccination. However, the EU Medicines Agency has stressed that people should continue to receive the OXFAM vaccine as a part of the fight against COVID-19.
The U.K. vaccine regulator said on April 7 that it was recommending that adults under age 30 be given other vaccines because of growing evidence that the Oxford-Astelicam (AZ) vaccine may cause blood clots.
The BBC reported that the UK’s Medicines and Healthcare Products Regulatory Agency assessed 79 cases of rare blood clots following vaccination in the UK as of the end of March, of which 19 people had died. “The Financial Times reported that of the 19 deaths, three were under the age of 30.
The UK Medicines and Healthcare Products Regulatory Agency said that although this does not prove that vaccines cause blood clots, the association is growing stronger.
The Central News Agency reported that two-thirds of the rare blood clots occurred in women, and the ages of those who lost their lives ranged from 18 to 79 years old. However, this still does not prove that the chance of blood clots varies by gender or age.
According to the UK Medicines and Healthcare Products Regulatory Agency, the efficacy of the Oxford-Astrican vaccine has been proven and blood clots are rare, so the benefits of vaccination continue to outweigh the risks for the vast majority of people. The Joint Committee on Vaccination and Immunisation, the UK’s vaccine regulator, subsequently said it recommended that young people aged 18 to 29 could be switched to his brand of vaccine if they had the option to do so.
Recent Comments